● Recruiting

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Condition: Non-small Cell Lung Cancer · Advanced Pancreatic Adenocarcinoma · Unresectable Pancreatic Cancer · Sponsor: Dana-Farber Cancer Institute

PhasePhase 1/Phase 2

Planned participants100

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Jonathan Leeman, MD · (617) 732-6452 · jonathe_leeman@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Brigham and Women's Hospital	Boston, Massachusetts, United States	Recruiting
Dana Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04789486